Generic semaglutide will hit the US market by 2027 and tirzepatide shortly after. Costs will drop 90%, the compounding problem will resolve, and the GLP-1 access question will be over.

The strongest form of the optimistic claim deserves to be stated first. Patent cliffs have produced dramatic price reductions in other classes — generic atorvastatin entered the US market at a 90%+ discount to branded Lipitor within eighteen months of patent expiration. Indian manufacturers launched semaglutide products in March 2026 at price points roughly 77% below branded Ozempic on the local market, and Apotex received the first US ANDA tentative approval for generic semaglutide injection on 10 April 2026 in partnership with Orbicular Pharmaceutical Technologies (Apotex Corp. press release, April 2026). The forward-looking case is not nothing. The specific claim that "the access question is over by 2027" is what the published timelines and regulatory mechanics do not support.

The US patent timeline. The Novo Nordisk composition-of-matter patent on semaglutide is US 8,129,343, with a US expiration date of 5 December 2031 after patent-term extension for regulatory delay (USPTO patent record on US 8129343; Maucher Jenkins: A Snapshot of the Semaglutide Patent Landscape). Method-of-use and formulation patents extend several years beyond — analyst modelling places practical US generic entry in 2032 with secondary patent contests running into 2033. The corresponding Indian composition patent (IN 262697) expired in March 2026, enabling the Sun Pharma, Dr. Reddy's, Cipla, Zydus, and Alkem launches there. Tirzepatide sits further out: the compound patent expires 5 January 2036 in the US, with formulation and method-of-use patents extending into 2039-2041 (DrugPatentWatch: Mounjaro patent expirations). The "by 2027" framing compresses a ten- to fifteen-year regulatory and patent runway into a single year.

The regulatory pathway is ANDA, not biosimilar. This is the load-bearing technical point. In March 2020 FDA's "biological product" definition was finalized as any alpha-amino-acid polymer greater than 40 amino acids in size, with insulin and human growth hormone transitioning into the 351(k) biosimilar pathway on 23 March 2020 (Katten: FDA Reduces Regulatory Uncertainty with New Finalized Rule). Semaglutide is 31 amino acids and tirzepatide is 39 — both fall below the threshold and are regulated as drugs, not biologics. Follow-on semaglutide and tirzepatide go through the abbreviated new drug application (ANDA) pathway under section 505(j) of the Federal Food, Drug and Cosmetic Act (FDA guidance: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin), not the 351(k) biosimilar pathway. The framing of semaglutide generics as analogous to Humira biosimilars is technically incorrect — the follow-on pathway is more favorable to generic entry than the biosimilar comparison assumes.

Where the peptide-specific complications enter. Synthetic peptides occupy a regulatory middle layer. ANDAs for synthetic peptide products are simpler than 351(k) biosimilar applications but require characterization steps small-molecule generics do not. FDA guidance on synthetic-peptide ANDAs requires the applicant to characterize all process- and product-related impurities, and any new impurity present at greater than 0.5% of the drug substance must be removed or supported by an immunogenicity risk assessment (FDA: Assessing Immunogenicity Risk of Peptides; De Groot et al., Pharmaceutical Research 2025). A case study comparing recombinant and synthetic liraglutide and semaglutide preparations documented substantially different impurity fingerprints across manufacturing methods. FDA approved the first complex generic of glucagon in December 2020 only after developing the analytical methods to characterize synthetic-peptide sameness; the parallel work for semaglutide and tirzepatide is in progress but not closed. The development cost for an ANDA-route synthetic-peptide generic sits between the $1-2M cost of a vanilla generic and the $100-300M cost of a 351(k) biosimilar.

What history says about follow-on price trajectories. For molecules adjacent to the GLP-1 RAs — peptide-protein follow-ons regulated under either the late-stage ANDA pathway or the 351(k) biosimilar pathway — the launch-day price drop has consistently been 15-40%, not 90%. Adalimumab biosimilar Amjevita launched January 2023 with a list-price discount of 5% (low-WAC version) or 55% (high-rebate version) versus reference Humira; heavier-discount entrants reached 85% list-price discounts only after multiple biosimilars had been on market 12-18 months and only at the wholesale list-price level rather than net-of-rebate (AJMC: Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price). Trastuzumab biosimilars launched 2019-2020 at 10-22% list discounts to Herceptin; average sales prices reached 28-58% below only by Q2 2022, after three years and four launched biosimilars (Center for Biosimilars: Increased Competition Is Lowering Trastuzumab Prices). Interchangeable insulin biosimilar Semglee launched July 2021 at a 65% WAC discount on the unbranded version, but realized patient-level savings have been substantially smaller because of PBM formulary and rebate dynamics. The honest pattern is incremental discount that grows over years, not a 90% same-day price drop.

Manufacturing capacity is the rate-limiter. The 2022-2024 GLP-1 supply shortage was not driven by demand exceeding patent-protected supply alone — it was driven by global manufacturing capacity for high-purity GLP-1 RA active pharmaceutical ingredient at GMP scale. Novo Holdings acquired Catalent in a $16.5B transaction completed December 2024, with Novo Nordisk paying $11B for three Catalent fill-finish facilities in Italy, Belgium, and Indiana that were already producing Wegovy and Ozempic under contract (Fierce Pharma: Novo antes up $16.5B to poach CDMO giant Catalent). Novo Nordisk indicated approximately $9B in additional 2025 capital expenditure for capacity expansion. Generic manufacturers face the same upstream synthesis and downstream fill-finish capacity question — the bottleneck is solid-phase peptide synthesis at GMP scale and aseptic fill-finish into multidose pens, not patent status. India's manufacturers built peptide-synthesis capacity in advance of the March 2026 patent expiration; US entrants will face the same lead-time problem plus the FDA bridge.

The compounded pathway has been substantially closed. The 503A and 503B compounding pathways that filled the 2023-2024 supply gap relied on the drug-shortage status of semaglutide and tirzepatide. FDA confirmed resolution of the tirzepatide shortage on 19 December 2024 and of the semaglutide shortage on 21 February 2025, with wind-down deadlines through May 2025 (FDA: Declaratory Order on Resolution of Shortages of Semaglutide Injection). The implication for the optimistic timeline is awkward: the compounded supply that was acting as a de facto price suppressant is being closed ahead of generic entry rather than after it. See the companion critic on compounded-GLP-1 equivalence for the bioequivalence layer that the closure addresses.

International parallel-import is a separate question. Indian, Bangladeshi, and Latin American generic semaglutide products at substantially lower prices exist outside the FDA-approved US supply chain. Parallel import, medical tourism, and patient-driven international purchasing are real workarounds, but they sit outside the FDA quality, immunogenicity, and pharmacovigilance frameworks. The trade-offs — variable manufacturing standards, absence of US adverse-event-reporting linkage, customs and prescribing-jurisdiction questions — are not what the "generic entry solves it" framing is describing.

Tirzepatide-specific considerations. Tirzepatide is a dual GLP-1 and GIP receptor agonist with substantial backbone engineering — a non-canonical lipophilic side chain at lysine-20 and a different fatty-acid linker geometry from semaglutide. As a 39-amino-acid synthetic peptide it remains drug-pathway rather than biologic-pathway, but the molecular complexity is higher than semaglutide's, and the synthesis, characterization, and impurity-profile work for follow-on tirzepatide is correspondingly harder. The compound patent extends to January 2036; combined with the additional analytical workload, US follow-on tirzepatide is realistically a late-2030s rather than a late-2020s phenomenon. The tirzepatide peptide page treats the molecule's pharmacology in detail; the liraglutide peptide page covers the older GLP-1 RA where Indian generic entry has already occurred.

What the page does forecast. Some price reduction will occur as ANDA-route synthetic-peptide generics launch — Apotex received tentative US approval in April 2026 and additional ANDA sponsors are in queue. The most likely trajectory is launch-day discounts in the 15-40% range during the early 2030s once US composition patents lapse, with deeper discounts (40-70%) emerging over several years as additional ANDA holders enter and Office of Generic Drugs reviews complete on the immunogenicity-risk packages. Full price normalization to small-molecule-generic levels — the 90%-off case the optimistic framing assumes — is not a published-evidence-supported expectation for the late 2020s. The honest reading is incremental improvement across the late-2020s and early-2030s, with interim patient access depending more on payer coverage, employer-plan inclusion, and the compounded-pathway enforcement contour than on patent expiration directly. The semaglutide, tirzepatide, liraglutide, and exenatide peptide pages treat the pharmacology that is the same regardless of supply-chain origin; the fat-loss decision guide and GLP-1 discontinuation playbook treat the clinical decision architecture downstream of the cost question. The access question is not over by 2027, and treating it as over risks misallocating both patient expectations and policy attention in the interim years that actually matter.